• Asbury Automotive Group reported past fourth-quarter 2025 revenue of US$4,676.5 million, up from US$4,504.5 million a year earlier, while quarterly net income fell to US$60 million and diluted EPS from continuing operations declined to US$3.10; for 2025 as a whole, revenue rose to US$17.99 billion and net income to US$492 million, alongside continued share repurchases and updated bylaws that lower the threshold for shareholders to call special meetings.
• The combination of an earnings per share miss relative to analyst expectations, ongoing buybacks that have retired 7.53% of shares since 2023, and board changes that increase shareholder influence and add private equity expertise is likely to focus investor attention on how Asbury balances capital allocation, governance, and profitability in the years ahead.
• We’ll now examine how the recent earnings shortfall, alongside significant buybacks, may reshape Asbury Automotive Group’s existing investment narrative.

We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Asbury Automotive Group Investment Narrative Recap

To own Asbury Automotive Group, you need to believe its dealership footprint, acquisitions like Herb Chambers, and growing parts and service operations can support resilient earnings even as the auto retail model evolves. The latest EPS miss and softer quarterly profit sharpen attention on execution, but they do not fundamentally alter the near term catalyst around integration and efficiency improvements or the key risk tied to leverage and industry shifts toward digital and direct sales.

Among the recent announcements, the completion of a US$330.29 million buyback retiring 7.53% of shares since 2023 stands out. Paired with mixed quarterly earnings, this amplifies the question of how Asbury will prioritize future cash between debt reduction, further acquisitions, and returning capital to shareholders, especially as investors weigh the benefits of reduced share count against balance sheet flexibility at a time of structural change in auto retail.

Yet beneath the headline EPS miss, investors should be aware of how rising EV adoption and digital car buying could steadily undermine Asbury’s traditional dealership economics and...

Asbury Automotive Group's narrative projects $21.6 billion revenue and $676.4 million earnings by 2028. This requires 7.7% yearly revenue growth and about a $136 million earnings increase from $540.0 million today.

Uncover how Asbury Automotive Group's forecasts yield a $255.50 fair value, a 10% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranking analysts already assumed only about 5.3 percent annual revenue growth to roughly US$20.2 billion and earnings of around US$605 million, reflecting a much more cautious view on pressures like EV adoption than the baseline narrative. After a quarter where EPS fell short, you can see how opinions can diverge sharply, and it is worth comparing these pessimistic assumptions with your own expectations for Asbury’s future.

Explore 2 other fair value estimates on Asbury Automotive Group - why the stock might be worth just $255.50!

Build Your Own Asbury Automotive Group Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Asbury Automotive Group research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Asbury Automotive Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Asbury Automotive Group's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our top stock finds are flying under the radar-for now. Get in early:

• Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 52 companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.